Staphylococcus aureus from Wound Swabs: Pathogen vs. Contaminant
Staphylococcus aureus isolated from a wound swab should generally be considered a true pathogen rather than a contaminant, as S. aureus is the most common cause of skin and soft tissue infections (SSTIs) and rarely represents colonization in wound specimens 1, 2.
Clinical Context Determines Significance
The interpretation depends critically on the clinical presentation:
When S. aureus is a True Pathogen (Treat):
- Purulent drainage present (pus, exudate, abscess) 1, 3
- Signs of infection: erythema, warmth, induration, pain
- Systemic signs: fever >38°C, tachycardia >90 bpm, tachypnea >24 breaths/min, WBC >12,000 or <4,000 1
- Cellulitis with purulent features 3
- Patient has failed initial drainage alone 3
- Immunocompromised host, diabetes, or other comorbidities 3
When to Question Clinical Significance:
- Clean, healing wound without inflammation
- No purulent drainage
- Patient clinically well without systemic signs
- Wound improving without antibiotics
Treatment Approach
For Mild Purulent SSTIs (Outpatient):
Primary intervention: Incision and drainage 1, 3
Add antibiotics if:
- Severe/extensive disease or multiple sites 3
- Rapid progression with cellulitis 3
- Systemic illness present 3
- Extremes of age, immunosuppression 3
- Failed drainage alone 3
Oral antibiotic options (5-10 days):
- For MSSA: Cephalexin or dicloxacillin 1
- For MRSA or unknown: Clindamycin, TMP-SMX, or doxycycline 3
- For both streptococci + MRSA coverage: Clindamycin alone OR TMP-SMX/doxycycline + amoxicillin 3
For Severe/Complicated SSTIs (Hospitalized):
Empiric IV therapy pending cultures:
- Vancomycin (first-line) 3
- Alternatives: Linezolid 600 mg IV/PO BID, daptomycin 4 mg/kg IV daily, or clindamycin 600 mg IV TID 3
Duration: 7-14 days, individualized to clinical response 3
Key Clinical Pitfalls
Culture interpretation errors:
- The 2014 IDSA guidelines explicitly state that cultures are NOT routinely recommended for simple cellulitis but ARE recommended for purulent infections, severe disease, systemic illness, or treatment failure 1, 3
- A recent 2024 study demonstrated that reporting typical wound pathogens susceptible to empiric therapy drove unnecessary antibiotic prescribing in 49.5% of cases where patients were not initially treated 4
- Exception-reporting (not reporting susceptible organisms) reduced post-report antibiotic initiation to 25.1% without increasing complications 4
MRSA considerations:
- Community-acquired MRSA is increasingly common, with rates of 41.7% in nasal colonization among diabetic patients 5
- 47.4% of wound S. aureus isolates were MRSA in one study 6
- Empiric MRSA coverage is warranted for: purulent cellulitis, penetrating trauma, known MRSA colonization, injection drug use, or systemic signs 1, 3
Resistance patterns:
- High rates of multidrug resistance exist: 100% penicillin resistance, 68.4% methicillin resistance in some populations 7
- Linezolid and vancomycin maintain 100% susceptibility 6
When Cultures Are Indicated
Obtain wound cultures when 1, 3:
- Patient receiving antibiotic therapy
- Severe local infection or systemic illness
- Failed initial treatment
- Recurrent infections
- Concern for outbreak
- Hospitalized patients with complicated SSTI
Do NOT routinely culture 1:
- Simple, uncomplicated cellulitis without purulent drainage
- Inflamed epidermoid cysts 1
Bottom Line
S. aureus in wound swabs is rarely a contaminant—it's the leading wound pathogen globally 2, 8. However, the presence of the organism alone should not automatically trigger antibiotic therapy. Treatment decisions must be based on clinical signs of active infection, not just microbiological results. For simple abscesses, drainage alone is often sufficient 1, 3. The recent evidence suggests that naming organisms in reports drives unnecessary prescribing 4, reinforcing that clinical judgment trumps laboratory results in wound management.